Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)
INR 208.85
(3.37%)
INR 208.85
(3.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 323.46 Million INR | -42.47% |
| 2022 | 363.96 Million INR | 38.73% |
| 2021 | 255.13 Million INR | 24.93% |
| 2020 | 198.72 Million INR | 111.4% |
| 2019 | 85.32 Million INR | 4.6% |
| 2018 | 93.35 Million INR | 203.96% |
| 2017 | -100.64 Million INR | -265.98% |
| 2016 | 59.62 Million INR | -50.61% |
| 2015 | 124.02 Million INR | 44.32% |
| 2014 | 88.24 Million INR | -20.79% |
| 2013 | 107.38 Million INR | 6.81% |
| 2012 | 103.77 Million INR | -39.49% |
| 2011 | 169.83 Million INR | 14.34% |
| 2010 | 145.3 Million INR | -9.64% |
| 2009 | 160.81 Million INR | 2.25% |
| 2008 | 153.63 Million INR | 18.87% |
| 2007 | 128.62 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 102.38 Million INR | 62.86% |
| 2024 Q2 | 179.39 Million INR | 113.64% |
| 2023 Q1 | 106.34 Million INR | 25.79% |
| 2023 Q2 | 106.39 Million INR | 0.05% |
| 2023 Q3 | 59.17 Million INR | -44.38% |
| 2023 FY | - INR | -42.47% |
| 2023 Q4 | 26.69 Million INR | -54.89% |
| 2022 Q3 | 103.75 Million INR | -26.01% |
| 2022 Q1 | 74.92 Million INR | 3135.66% |
| 2022 FY | - INR | 38.73% |
| 2022 Q4 | 84.53 Million INR | -18.52% |
| 2022 Q2 | 140.23 Million INR | 87.17% |
| 2021 Q4 | -2.46 Million INR | -103.14% |
| 2021 FY | - INR | 24.93% |
| 2021 Q3 | 78.58 Million INR | -18.88% |
| 2021 Q2 | 96.86 Million INR | -4.06% |
| 2021 Q1 | 100.96 Million INR | 35.72% |
| 2020 FY | - INR | 111.4% |
| 2020 Q3 | 70.17 Million INR | 33.47% |
| 2020 Q2 | 52.57 Million INR | 53.25% |
| 2020 Q1 | 34.3 Million INR | 83.57% |
| 2020 Q4 | 74.39 Million INR | 6.01% |
| 2019 Q4 | 18.68 Million INR | -41.87% |
| 2019 FY | - INR | 4.6% |
| 2019 Q1 | 29.08 Million INR | -27.11% |
| 2019 Q3 | 32.14 Million INR | 8.92% |
| 2019 Q2 | 29.51 Million INR | 1.49% |
| 2018 Q1 | 13.33 Million INR | 221.18% |
| 2018 Q2 | 26.59 Million INR | 99.39% |
| 2018 Q3 | 24.79 Million INR | -6.79% |
| 2018 Q4 | 39.9 Million INR | 60.95% |
| 2018 FY | - INR | 203.96% |
| 2017 Q1 | -37.69 Million INR | -772.68% |
| 2017 Q4 | -11 Million INR | 46.17% |
| 2017 Q3 | -20.44 Million INR | 45.24% |
| 2017 Q2 | -37.34 Million INR | 0.94% |
| 2017 FY | - INR | -265.98% |
| 2016 Q1 | 24.54 Million INR | -50.18% |
| 2016 FY | - INR | -50.61% |
| 2016 Q2 | 22.28 Million INR | -9.24% |
| 2016 Q3 | 9.94 Million INR | -55.37% |
| 2016 Q4 | 5.6 Million INR | -43.64% |
| 2015 FY | - INR | 44.32% |
| 2015 Q4 | 49.26 Million INR | 101.85% |
| 2015 Q3 | 24.4 Million INR | -3.76% |
| 2015 Q2 | 25.36 Million INR | -0.83% |
| 2015 Q1 | 25.57 Million INR | 65.08% |
| 2014 Q3 | 18.7 Million INR | -24.9% |
| 2014 Q2 | 24.9 Million INR | -14.9% |
| 2014 Q1 | 29.26 Million INR | -22.36% |
| 2014 FY | - INR | -20.79% |
| 2014 Q4 | 15.49 Million INR | -17.18% |
| 2013 Q1 | 20.49 Million INR | 13.25% |
| 2013 Q2 | 19.24 Million INR | -6.1% |
| 2013 Q4 | 37.69 Million INR | 25.85% |
| 2013 Q3 | 29.95 Million INR | 55.64% |
| 2013 FY | - INR | 6.81% |
| 2012 Q1 | 19.6 Million INR | -41.18% |
| 2012 Q2 | 27.02 Million INR | 37.88% |
| 2012 Q3 | 35.81 Million INR | 32.51% |
| 2012 Q4 | 18.09 Million INR | -49.47% |
| 2012 FY | - INR | -39.49% |
| 2011 FY | - INR | 14.34% |
| 2011 Q3 | 49.6 Million INR | 0.66% |
| 2011 Q2 | 49.27 Million INR | 0.0% |
| 2011 Q4 | 33.32 Million INR | -32.82% |
| 2010 FY | - INR | -9.64% |
| 2009 FY | - INR | 2.25% |
| 2008 FY | - INR | 18.87% |
| 2007 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 96.636% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.476% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 95.287% |
| Granules India Limited | 8.6 Billion INR | 96.241% |
| Indoco Remedies Limited | 2.64 Billion INR | 87.78% |
| Achyut Healthcare Limited | 524 Thousand INR | -61629.008% |
| Ajanta Pharma Limited | 12.56 Billion INR | 97.426% |
| Alkem Laboratories Limited | 24.19 Billion INR | 98.663% |
| Alpa Laboratories Limited | 86.12 Million INR | -275.562% |
| Brooks Laboratories Limited | 41.72 Million INR | -675.163% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 86.275% |
| Bajaj HealthCare Limited | 444.51 Million INR | 27.233% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 78.13% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.634% |
| Eris Lifesciences Limited | 6.98 Billion INR | 95.37% |
| FDC Limited | 4.4 Billion INR | 92.651% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 97.149% |
| Gufic Biosciences Limited | 1.48 Billion INR | 78.152% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 95.286% |
| Ipca Laboratories Limited | 13.29 Billion INR | 97.568% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 490.997% |
| Lasa Supergenerics Limited | -65.08 Million INR | 597.019% |
| Laurus Labs Limited | 8 Billion INR | 95.96% |
| Lupin Limited | 36.96 Billion INR | 99.125% |
| Mankind Pharma Limited | 28.09 Billion INR | 98.849% |
| Medicamen Biotech Limited | 245.66 Million INR | -31.67% |
| Medico Remedies Limited | 150.37 Million INR | -115.098% |
| Megasoft Limited | 284.73 Million INR | -13.602% |
| NATCO Pharma Limited | 18.79 Billion INR | 98.279% |
| Piramal Pharma Limited | 13.05 Billion INR | 97.522% |
| RPG Life Sciences Limited | 1.28 Billion INR | 74.759% |
| Sigachi Industries Limited | 883.39 Million INR | 63.385% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.766% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 93.084% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 24.825% |
| Unichem Laboratories Limited | 742.35 Million INR | 56.428% |
| Wanbury Limited | 985.49 Million INR | 67.178% |
| Windlas Biotech Limited | 781.72 Million INR | 58.622% |
| ZIM Laboratories Limited | 462.09 Million INR | 30.002% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.425% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 108.669% |
| Divi's Laboratories Limited | 25.43 Billion INR | 98.728% |
| Hester Biosciences Limited | 539.47 Million INR | 40.041% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 89.27% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 52.609% |
| Bal Pharma Limited | 345.59 Million INR | 6.404% |
| Strides Pharma Science Limited | 3.76 Billion INR | 91.408% |
| Venus Remedies Limited | 711.8 Million INR | 54.558% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 91.726% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 79.316% |
| Shilpa Medicare Limited | 2.58 Billion INR | 87.501% |
| Aarti Drugs Limited | 3.24 Billion INR | 90.043% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 87.591% |
| Suven Life Sciences Limited | -992.78 Million INR | 132.581% |
| Ind-Swift Limited | 1.06 Billion INR | 69.63% |
| Valiant Laboratories Limited | 12.73 Million INR | -2439.132% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 96.535% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 111.462% |
| Themis Medicare Limited | 562.6 Million INR | 42.507% |
| Hikal Limited | 2.69 Billion INR | 87.985% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 99.076% |
| Sequent Scientific Limited | 549.8 Million INR | 41.168% |
| Novartis India Limited | 1.26 Billion INR | 74.517% |
| Wockhardt Limited | 1.08 Billion INR | 70.05% |
| Jubilant Pharmova Limited | 8 Billion INR | 95.96% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -2376.344% |
| Neuland Laboratories Limited | 4.74 Billion INR | 93.188% |
| Morepen Laboratories Limited | 1.72 Billion INR | 81.259% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -12.537% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -84.891% |